Acute myocardial infarction - commonly known as a heart attack - is the leading cause of death worldwide. Current treatments manage symptoms, but they don’t regenerate the damaged tissue. Survivors are left with permanent injury and a lasting impact on their quality of life, with high costs of ongoing care.
Stem cell therapies and synthetic scaffolds have tried to solve this for over a decade, and consistently fallen short: cell-based approaches face immune rejection and fail to couple with the heart's rhythm.
Our lead product is an injectable hydrogel made from decellularized extracellular matrix, the natural scaffold that surrounds and supports heart cells.
Unlike synthetic alternatives, it keeps the matrix's native structure and bioactive signaling intact, stimulating existing cardiomyocytes to divide and new blood vessels to form.
We're building partnerships with clinical, academic and industry leaders in regenerative cardiac care, and we're raising to advance toward first-in-human trials. If you'd like to review our data or discuss a collaboration or investment, get in touch.
Delaware, USA | Buenos Aires, Argentina
lucas@corasus.bio